IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in the 2023 Guggenheim Oncology Conference, scheduled for February 9, 2023, at 7:45 AM PT. The event will feature a fireside chat with President and CEO Yujiro S. Hata and Chief Scientific Officer Michael White, hosted by equity research analyst Charles Zhu, Ph.D. A live audio webcast of the discussion will be available on IDEAYA's website, with a replay accessible for 30 days post-event. IDEAYA focuses on synthetic lethality and precision medicine, developing targeted therapeutics based on molecular diagnostics to enhance treatment efficacy for selected patient populations.
- None.
- None.
2023
Fireside chat with
A live audio webcast of the event will be available, as permitted by conference host, at the "Investors/ Events" section of the IDEAYA website at https://ir.ideayabio.com/events. A replay of the webcast will be accessible for 30 days following the live event.
About
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on
Investor and Media Contact
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-the-2023-guggenheim-oncology-conference-301735419.html
SOURCE
FAQ
When is IDEAYA Biosciences participating in the 2023 Guggenheim Oncology Conference?
Who will represent IDEAYA Biosciences at the Guggenheim Oncology Conference?
Where can I watch the IDEAYA Biosciences conference presentation?
How long will the IDEAYA conference webcast be available for replay?
What is the focus of IDEAYA Biosciences' research?
